A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study

Transplant Infectious Disease

Volumn 19, Issue 4, 2017, Pages

  Piñana, José Luis ^a,b,c   Hernández Boluda, Juan Carlos ^a   Calabuig, Marisa ^a   Ballester, Isabel ^a   Marín, Manuela ^a   Madrid, Silvia ^a   Teruel, Anabel ^a   Terol, María José ^a   Navarro, David ^a,d   Solano, Carlos ^a,d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF VALENCIA   (Spain)

Author keywords

allogeneic hematopoietic stem cell transplantation; ECIL 4; human parainfluenza virus; immunodeficiency scoring index; oral ribavirin; respiratory syncytial virus; respiratory viral infection

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIFUNGAL AGENT; BUSULFAN; C REACTIVE PROTEIN; CEPHALOSPORIN; CORTICOSTEROID; CYCLOSPORIN; FLUDARABINE; IMMUNOGLOBULIN; MELPHALAN; METHOTREXATE; MYCOPHENOLATE MOFETIL; QUINOLONE DERIVATIVE; RAPAMYCIN; RIBAVIRIN; TACROLIMUS; THYMOCYTE ANTIBODY; ANTIVIRUS AGENT;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; BRONCHIOLITIS; BRONCHITIS; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; COMMON COLD; COUGHING; DISEASE COURSE; ERYTHROBLASTOPENIA; FEMALE; FEVER; GRAFT RECIPIENT; HLA MATCHING; HODGKIN DISEASE; HOSPITAL ADMISSION; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION PREVENTION; KIDNEY ALLOGRAFT; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; LUNG INFILTRATE; LUNG LAVAGE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MIXED INFECTION; MORTALITY RATE; MULTIPLE MYELOMA; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NASOPHARYNGEAL ASPIRATION; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; NOSE SMEAR; OTITIS; OVERALL SURVIVAL; PARAINFLUENZA VIRUS INFECTION; PARAMYXOVIRINAE; PATIENT HISTORY OF CHEMOTHERAPY; PHARYNGITIS; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; RELAPSE; RESPIRATORY FAILURE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RHINORRHEA; SINUSITIS; SNEEZING; SORE THROAT; STEROID THERAPY; TONSILLITIS; TRACHEITIS; TREATMENT DURATION; VIRAL RESPIRATORY TRACT INFECTION; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS DETECTION; VIRUS ISOLATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PARAMYXOVIRUS INFECTION; STEM CELL TRANSPLANTATION; VIROLOGY;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PARAMYXOVIRIDAE INFECTIONS; PILOT PROJECTS; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RIBAVIRIN; STEM CELL TRANSPLANTATION;

EID: 85024875224     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12729     Document Type: Article

References (30)

1. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117:2755-2763.
2. Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis. 2011;24:333.
3. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: Single-center study and review of the literature. Clin Infect Dis. 2008;46:402-412.
4. Chemaly RF, Hanmod SS, Rathod DB, et al. The characteristics and outcomes of parainfluenza virus infections in 200 patients with leukemia or recipients of hematopoietic stem cell transplantation. Blood. 2012;119:2738-2745.
5. Ustun C, Slabý J, Shanley RM, et al. Human parainfluenza virus infection after hematopoietic stem cell transplantation: Risk factors, management, mortality, and changes over time. Biol Blood Marrow Transplant. 2012;18:1580-1588.
6. Ljungman P, Ward K, Crooks B, et al. Viral infections-Respiratory virus infections after stem cell transplantation: A prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow. Bone Marrow Transplant. 2001;28:479-484.
7. Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. Ann Pharmacother. 2012;46:558-566.
8. Boeckh M, Englund J, Li Y, et al. Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. Clin Infect Dis. 2007;44:245-249.
9. Hirsch HH, Martino R, Ward KN, Boeckh M, Einsele H, Ljungman P. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis. 2013;56:258-266.
10. Preston SL, Drusano GL, Glue P, Nash J, Gupta S, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother. 1999;43:2451-2456.
11. Beaird OE, Freifeld A, Ison MG, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: A survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis. 2016;18(2):210-215.
12. Shah DP, Ghantoji SS, Ariza-Heredia EJ, et al. Immunodeficiency scoring index to predict poor outcomes in hematopoietic cell transplant recipients with RSV infections. Blood. 2014;123:3263-3268.
13. Kmeid J, Vanichanan J, Shah DP, et al. Outcomes of influenza infections in hematopoietic cell transplant recipients: Application of an immunodeficiency scoring index. Biol Blood Marrow Transplant. 2015;22:542-548.
14. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. PLoS Pathog. 2013;9:e1003057.
15. Martino R, Piñana J, Parody R, et al. Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. Bone Marrow Transplant. 2009;44:749-756.
16. Costa E, Rodríguez-Domínguez M, Clari MÁ, Giménez E, Galán JC, Navarro D. Comparison of the performance of 2 commercial multiplex PCR platforms for detection of respiratory viruses in upper and lower tract respiratory specimens. Diagn Microbiol Infect Dis. 2015;82:40-43.
17. Seo S, Xie H, Campbell AP, et al. Parainfluenza virus lower respiratory tract disease after hematopoietic cell transplant: Viral detection in the lung predicts outcome. Clin Infect Dis. 2014;58:1357-1368.
18. Lewinsohn DM, Bowden RA, Mattson D, Crawford SW. Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation. Antimicrob Agents Chemother. 1996;40:2555-2557.
19. Sparrelid E, Ljungman P, Ekelöf-Andström E, et al. Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections. Bone Marrow Transplant. 1997;19:905-908.
20. Marcelin JR, Wilson JW, Razonable RR; Mayo Clinic Hematology/Oncology and Transplant Infectious Diseases Services. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients. Transpl Infect Dis. 2014;16:242-250.
21. Shah DP, Ghantoji SS, Shah JN, et al. Impact of aerosolized ribavirin on mortality in 280 allogeneic haematopoietic stem cell transplant recipients with respiratory syncytial virus infections. J Antimicrob Chemother. 2013;68:1872-1880.
22. Dignan FL, Clark A, Aitken C, et al.; Haemato-oncology Task Force of the British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation and the UK Clinical Virology Network. BCSH/BSBMT/UK clinical virology network guideline: Diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation. Br J Haematol. 2016;173:380-393.
23. Waghmare A, Englund JA, Boeckh M. How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation. Blood. 2016;127:2682-2692.
24. Chemaly RF, Shah DP, Boeckh MJ. Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies. Clin Infect Dis. 2014;59(Suppl 5):S344-S351.
25. Chemaly RF, Torres HA, Munsell MF, et al. An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. J Infect Dis. 2012;206:1367-1371.
26. Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003;32:1085-1088.
27. El-Bietar J, Nelson A, Wallace G, et al. RSV infection without ribavirin treatment in pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2016;51:1382-1384.
28. Casey J, Morris K, Narayana M, Nakagaki M, Kennedy G. Oral ribavirin for treatment of respiratory syncitial virus and parainfluenza 3 virus infections post allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2013;48:1558-1561.
29. Chakrabarti S, Collingham K, Holder K, Fegan C, Osman H, Milligan D. Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: A pilot study. Bone Marrow Transplant. 2001;28:759-763.
30. Lehners N, Tabatabai J, Prifert C, et al. Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders. PLoS One. 2016;11:e0148258.